DaVita Inc. - $DVA STOCK NEWS

DaVita (NYSE: DVA) plans to power its global operations with 100% renewable energy by 2025, partnering with ACCIONA Energía in Spain. The company has already achieved this goal in its North American operations. DaVita's commitment to sustainability includes reducing carbon footprint, saving water, and upgrading facilities with energy-efficient solutions.

DaVita Inc. (NYSE: DVA) has scheduled its 1st Quarter 2024 Investor Conference Call for May 2, 2024, at 5:00 p.m. Eastern Time. The company will discuss its first-quarter results, which will be released after market close on the same day. The call will be webcast and accessible through the DaVita IR web page. Investors can join the call via webcast or dial-in, with a replay available on the company's website for those unable to listen live.

DaVita Inc. appoints new independent director, Dennis Pullin, to its Board of Directors, enhancing healthcare expertise.

The American Diabetes Association (ADA) and DaVita (DVA) expand collaboration to advance chronic disease prevention, focusing on diabetes and chronic kidney disease (CKD) during National Kidney Month. DaVita contributes $1.5 million to support ADA initiatives targeting at-risk individuals. Efforts include creating educational materials, piloting a registered dietitian program, and sponsoring State of Diabetes events.

DaVita Inc. (DVA) CFO and VP of Investor Relations to participate in fireside chat at Barclays Global Healthcare Conference 2024.

DaVita Inc (NYSE: DVA) expands its international operations in Latin America through strategic acquisitions, making it the largest dialysis services provider in the region. The $300M USD deal with Fresenius Medical Care involves four acquisitions, boosting DaVita's presence in Brazil, Colombia, Chile, and Ecuador.

DaVita Inc. (DVA) CFO and VP to participate in a fireside chat at TD Cowen's Health Care Conference 2024.

DaVita Inc. (DVA) reported strong financial and operating results for the quarter and year ended December 31, 2023, with consolidated revenues of $3.146 billion and $12.140 billion, operating income of $390 million and adjusted operating income of $415 million for the quarter, and $1,603 million and $1,734 million for the year, diluted earnings per share from continuing operations of $1.62 and adjusted diluted earnings per share of $1.87 for the quarter, and $7.42 and $8.47 for the year, operating cash flow of $485 million and free cash flow of $258 million for the quarter, and $2,059 million and $1,236 million for the year. DaVita also repurchased 2,903,832 shares of common stock at an average price of $97.82 per share. The company provided insights into U.S. dialysis metrics, revenue per treatment, patient care costs per treatment, and general and administrative expenses, highlighting the primary drivers of changes in these areas. Additionally, DaVita discussed key items impacting the quarter and year, such as integrated kidney care revenues, closure costs, severance costs, goodwill impairment, and share repurchases.

DaVita Inc. (NYSE: DVA) is set to hold its quarterly conference call to discuss fourth quarter results on February 13, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. The call will be webcast and can be accessed at the DaVita IR web page. Investors unable to listen to the conference call will be able to access a replay via the company's website at investors.davita.com.